Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
暂无分享,去创建一个
N. Rizvi | H. Kluger | M. Callahan | L. Vitale | T. Keler | M. Yellin | R. Sanborn | A. Halim | Tracey Rawls | T. Davis | M. Pishvain